NetraMark and CAMH Announce Research Award to Advance AI-Driven Discovery in Schizophrenia and Depression

Executive Summary

• NetraMark Holdings Inc. received the Ontario Research Fund – Research Excellence (ORF‑RE) Award in partnership with the Centre for Addiction and Mental Health (CAMH).
• The award enables deployment of NetraMark’s NetraAI platform on CAMH’s high‑performance computing cluster to analyze genetic/epigenetic data from schizophrenia and major depressive disorder studies.
• The collaboration will generate explainable patient subpopulations, support precision‑treatment strategies, and enhance NetraAI’s capabilities for pharmaceutical sponsors in the psychiatric space.

Key Details

• Award: Ontario Research Fund – Research Excellence (ORF‑RE) Award recognizing innovative research partnerships in Ontario.
• Collaboration Scope:
• Installation of NetraAI software on CAMH’s secure research cluster, performed by CAMH IT with on‑site support from NetraMark.
• Analysis of de‑identified genetic and epigenetic data from schizophrenia and major depressive disorder studies funded by ORF‑RE.
• Evaluation of an additional “bonus dataset” comprising Ontario Health Insurance Plan (OHIP) administrative data for cost‑effectiveness and health‑system impact analyses.
• Objectives:
• Identify explainable patient subpopulations to clarify biological subtypes in psychiatric disorders.
• Support next‑generation precision‑treatment strategies and improve clinical trial outcomes for pharmaceutical sponsors.
• Quotes:
• Dr. James Kennedy (CAMH): “This collaboration integrates NetraMark’s unique AI approach with CAMH’s deep genomic and clinical datasets… to personalize treatment for each individual patient living with complex mental health illnesses.”
• Dr. Joseph Geraci (NetraMark, CSO/CTO): “Combining their datasets with NetraAI’s explainable AI framework allows us to uncover biologically grounded subpopulations that have previously eluded traditional analytics… contributing to next‑generation precision‑medicine approaches for mental health.”
• Strategic Impact: Enhances NetraMark’s market positioning in psychiatric‑focused AI analytics, potentially expanding its addressable pharmaceutical client base and generating new revenue streams from precision‑medicine services.

Notable Quotes

• “It makes me proud to have my work recognized through this award and to collaborate with CAMH… We believe this work will contribute to next‑generation precision‑medicine approaches for mental health and also improve clinical trial outcomes.” – Dr. Joseph Geraci, Founder & CSO/CTO, NetraMark.